Molecular forms of neurogranin in cerebrospinal fluid.


Journal

Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R

Informations de publication

Date de publication:
05 2021
Historique:
revised: 17 08 2020
received: 21 02 2020
accepted: 18 11 2020
pubmed: 30 11 2020
medline: 22 6 2021
entrez: 29 11 2020
Statut: ppublish

Résumé

Neurogranin (Ng) is a 78 amino acid neuronal protein and a biomarker candidate for Alzheimer's disease (AD). Ng has been suggested to bind to calmodulin and phosphatidic acid via its centrally located IQ domain. Ng is cleaved within this functionally important domain, yielding the majority of fragments identified in cerebrospinal fluid (CSF), suggesting that cleavage of Ng may be a mechanism to regulate its function. Up to now, Ng has been shown to be present in CSF as both C-terminal fragments as well as full-length protein. To obtain an overview of the different molecular forms of Ng present in CSF, we show by size exclusion chromatography (SEC), immunoblotting, immunoprecipitation, and MS that Ng is present in CSF as several molecular forms. Besides monomeric full-length Ng, also higher molecular weight forms of Ng, and C-terminal- and previously not identified N-terminal fragments were observed. We found by immunodepletion that C-terminal peptides contribute on average to ~50% of the total-Ng ELISA signal in CSF samples. There were no differences in the overall C-terminal fragment/total-Ng ratios between samples from AD and control groups. In addition, we found that monomeric Ng and its C-terminal fragments bind to heparin via a heparin-binding motif, which might be of relevance for their export mechanism from neurons. Taken together, this study highlights the presence of several molecular forms of Ng in CSF, comprising monomeric full-length Ng, and N- and C-terminal truncations of Ng, as well as larger forms of still unknown composition.

Identifiants

pubmed: 33249594
doi: 10.1111/jnc.15252
pmc: PMC8378242
doi:

Substances chimiques

NRGN protein, human 0
Neurogranin 132654-77-4
Heparin 9005-49-6

Banques de données

RefSeq
['RRID:AB_628497', 'RRID:AB_2687626', 'RRID:AB_1310252', 'RRID:AB_330924', 'RRID:AB_2783009']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

816-833

Subventions

Organisme : Medical Research Council
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.

Références

Alzheimers Dement. 2015 Oct;11(10):1180-90
pubmed: 25533203
J Biol Chem. 1999 Mar 19;274(12):7689-94
pubmed: 10075657
Biochem J. 2007 May 15;404(1):31-43
pubmed: 17295609
Mol Neurodegener. 2018 Aug 29;13(1):47
pubmed: 30157938
Sci Rep. 2013;3:1392
pubmed: 23462742
FEBS Lett. 2002 Feb 20;513(1):107-13
pubmed: 11911888
Neurobiol Dis. 2020 Feb;134:104645
pubmed: 31669672
J Neurosci. 2004 Nov 24;24(47):10660-9
pubmed: 15564582
Int Psychogeriatr. 1998 Mar;10(1):11-23
pubmed: 9629521
Neurosci Lett. 2019 May 14;701:125-131
pubmed: 30807796
Acta Neuropathol Commun. 2016 Mar 31;4:34
pubmed: 27036949
Acta Neuropathol. 2019 Jan;137(1):89-102
pubmed: 30244311
Clin Chem. 2018 Jun;64(6):927-937
pubmed: 29523639
J Biol Chem. 1995 Mar 24;270(12):6741-50
pubmed: 7896819
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11232-7
pubmed: 11016969
J Neurosci. 1990 Dec;10(12):3782-92
pubmed: 2269883
IUBMB Life. 2010 Aug;62(8):597-606
pubmed: 20665622
J Alzheimers Dis. 2016 Jul 6;53(4):1523-38
pubmed: 27392859
Neural Regen Res. 2020 May;15(5):861-862
pubmed: 31719249
Alzheimers Dement. 2015 Dec;11(12):1461-1469
pubmed: 26092348
Blood. 2003 Mar 15;101(6):2285-93
pubmed: 12433680
Neurosci Biobehav Rev. 2015 Dec;59:208-37
pubmed: 26562682
Arteriosclerosis. 1989 Jan-Feb;9(1):21-32
pubmed: 2463827
J Neurochem. 2021 May;157(3):816-833
pubmed: 33249594
Immunol Rev. 2000 Aug;176:216-46
pubmed: 11043780
J Mass Spectrom. 2012 May;47(5):591-603
pubmed: 22576872
Neurochem Int. 2018 Dec;121:38-49
pubmed: 30342961
Exp Neurol. 2005 Oct;195(2):330-41
pubmed: 16004982
Brain Res. 2010 Nov 29;1362:13-22
pubmed: 20875798
Molecules. 2017 May 15;22(5):
pubmed: 28505124
Cell Rep. 2018 May 15;23(7):2039-2055
pubmed: 29768203
J Biol Chem. 2015 Nov 27;290(48):28623-30
pubmed: 26453306
Alzheimers Res Ther. 2015 Jul 01;7(1):40
pubmed: 26136856
EMBO J. 2009 Oct 7;28(19):3027-39
pubmed: 19713936
J Neurochem. 2001 Nov;79(4):859-67
pubmed: 11723178
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):846-853
pubmed: 31097472
J Biol Chem. 1991 Jan 5;266(1):229-37
pubmed: 1824695
J Biol Chem. 1997 Dec 12;272(50):31617-24
pubmed: 9395501

Auteurs

Faisal Hayat Nazir (FH)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Elena Camporesi (E)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Gunnar Brinkmalm (G)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Tammaryn Lashley (T)

Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Institute of Neurology, London, UK.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.

Christina E Toomey (CE)

Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Institute of Neurology, London, UK.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute at UCL, London, UK.

Hlin Kvartsberg (H)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Henrik Zetterberg (H)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute at UCL, London, UK.

Kaj Blennow (K)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Bruno Becker (B)

Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH